RNA vaccines are emerging as the most promising approach for vaccine development, enabling a rapid response to COVID-19 and future pandemics. Precision NanoSystems (PNI) is a leading provider of technologies for the development of RNA vaccines and medicines, and works with over 200 drug development companies and academic institutions. PNI and many of its partners are now developing vaccine candidates for COVID-19.
RNA vaccines work by providing the code and instructions to your cells to produce representative but harmless parts of the virus. Your immune system uses these virus parts to train itself to defend against future infections. RNA vaccines are a disruptive technology as they’re significantly faster and easier to develop and manufacture than existing vaccine technologies. Through PNI’s platform, RNA vaccines can be rapidly produced, manufactured in-country, and evolved to respond to new or changing viruses.
PNI’s RNA vaccine platform comprises its proprietary lipid nanoparticle delivery system, NanoAssemblr® manufacturing technology, and its extensive drug development expertise. The company’s platform is ushering in the next wave of medicines in infectious diseases, cancer, and rare diseases.
